Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
1.320
-0.050 (-3.65%)
At close: Feb 12, 2026, 4:00 PM EST
1.320
0.00 (0.01%)
After-hours: Feb 12, 2026, 4:21 PM EST
Lyra Therapeutics Revenue
Lyra Therapeutics had revenue of $25.00K in the quarter ending September 30, 2025, a decrease of -87.18%. This brings the company's revenue in the last twelve months to $600.00K, down -59.21% year-over-year. In the year 2024, Lyra Therapeutics had annual revenue of $1.53M, down -1.54%.
Revenue (ttm)
$600.00K
Revenue Growth
-59.21%
P/S Ratio
3.16
Revenue / Employee
$20,000
Employees
30
Market Cap
2.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.53M | -24.00K | -1.54% |
| Dec 31, 2023 | 1.56M | 195.00K | 14.31% |
| Dec 31, 2022 | 1.36M | 1.08M | 378.25% |
| Dec 31, 2021 | 285.00K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 11.79M |
| Onconetix | 1.22M |
| Scinai Immunotherapeutics | 1.15M |
| HCW Biologics | 422.03K |
| Cardio Diagnostics Holdings | 15.78K |
| Ernexa Therapeutics | 1,000.00 |
LYRA News
- 4 weeks ago - Lyra Therapeutics Provides Corporate Update - GlobeNewsWire
- 3 months ago - Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study - GlobeNewsWire
- 6 months ago - Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 months ago - Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 8 months ago - Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst - Seeking Alpha
- 9 months ago - Why Is Lyra Therapeutics Stock Surging Over 400% On Monday? - Benzinga
- 9 months ago - Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - GlobeNewsWire